Correction to: Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE)
Kaplan–Meier survival curves of psoriatic arthritis patients on treatment with ustekinumab subdivided into biologic-naïve and tumor necrosis factor inadequate responder (TNF-IR) patients (a), by clinical subset (b), by prior TNF inhibitor (etanercept, ETN; anti-TNF monoclonal antibody, TNFi mAb) (c), and by co-therapy with MTX (d)